Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RHEB | Q15382 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1335301 | 0.82 | NUDT1 (0.37) | NPC1RAB9AMEN1KMT2ARHEB | |
| SCHEMBL3011647 | 0.80 | ALDH1A1 (0.34) | NPC1RAB9AMEN1KMT2ARHEB | |
| SCHEMBL2231635 | 0.77 | MTOR (0.44) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL3877175 | 0.77 | HPGD (0.40) | NPC1RAB9AMEN1KMT2ARHEB | |
| SCHEMBL5120449 | 0.76 | KDM4E (0.38) | RHEBKDM4EALDH1A1JAK2 | |
| SCHEMBL2869368 | 0.76 | DYRK1A (0.34) | NPC1RAB9AMEN1KMT2A | |
| SCHEMBL4367099 | 0.71 | ALDH1A1 (0.46) | MEN1KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL102202 | 0.68 | MEN1 (0.33) | NPC1RAB9AMEN1KMT2A | |
| SCHEMBL1335315 | 0.68 | SMN1; SMN2 (0.42) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL1021282 | 0.67 | MAPT (0.39) | NPC1RAB9AKMT2AKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107793417-A | Pyrrolo- [2,3 d] pyrimidines and its salt, and preparation method and pharmaceutical usage | 复旦大学 | 2018-03-13 | — | — | CN | claimed |
| WO-2024131942-A1 | CYCLOPROPANE TLR7 AND TLR8 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海深势唯思科技有限责任公司 | 2024-06-27 | — | — | WO | disclosed |
| CN-118239959-A | Cyclopropane TLR7 and 8 inhibitor and preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024073073-A2 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2023020512-A1 | SUBSTITUTED PYRIDINE ANALOGUE, PREPARATION METHOD THEREFOR, AND USE THEREOF AS AHR MODULATOR | 成都奥睿药业有限公司 | 2023-02-23 | — | — | WO | disclosed |
| EP-3638227-B1 | SPIROCYCLIC INDOLINES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2022-08-10 | — | — | EP | disclosed |
| US-11136326-B2 | Pyrrolopyrimidine derivatives as TAM inhibitors | INCYTE CORPORATION (US) | 2021-10-05 | — | — | US | disclosed |
| US-11052076-B2 | Spirocyclic indolines as IL-17 modulators | UCB Biopharma SRL (BE) | 2021-07-06 | — | — | US | disclosed |
| CN-109748915-B | Inhibitors of influenza virus replication and methods of use and uses thereof | 广东东阳光药业有限公司 | 2021-03-26 | — | — | CN | disclosed |
| US-7598256-B2 | Parkinson's disease; antidepressants; cognition activators; attention deficit disorders; narcolepsy; N,N-dimethyl-4-(2-furyl)-1H-pyrrolo[2,3- d]pyrimidine-2-amine | VERNALIS RESEARCH LIMITED (GB) | 2009-10-06 | — | — | US | disclosed |
| WO-2009020990-A1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-12 | — | — | WO | disclosed |
| EP-1363639-B1 | PYRROLO 2,3-d PYRIMIDINE AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2008-08-20 | — | — | EP | disclosed |
| US-20080004295-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-03 | — | — | US | disclosed |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-7098333-B2 | Pyrrolo[2,3-d]pyrimidine and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2006-08-29 | — | — | US | disclosed |
| US-20060128731-A1 | Pyrrolo [2,3-d] pyrimidine and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2006-06-15 | — | — | US | disclosed |
| US-20040092537-A1 | Pyrrolo[2,3-d]pyrimidine and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2004-05-13 | — | — | US | disclosed |
| EP-0673376-B1 | BICYCLIC PYRIMIDINE COMPOUNDS, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS | ADIR (FR) | 1996-05-22 | — | — | EP | disclosed |
| US-5508277-A | Bicyclic pyrimidines | ADIR ET COMPAGNIE (FR) | 1996-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128731-A1 | Pyrrolo [2,3-d] pyrimidine and their use as purinergic receptor antagonists | CHRNA6, CNR1, ADORA2A | NPC1 801/4885RAB9A 728/4885MEN1 4873/4885 |
| US-11136326-B2 | Pyrrolopyrimidine derivatives as TAM inhibitors | FLT3, MERTK, MIF | NPC1 3777/4885RAB9A 1615/4885MEN1 2493/4885 |
| US-11052076-B2 | Spirocyclic indolines as IL-17 modulators | IL17A, IL2, IL18 | NPC1 1898/4885RAB9A 2204/4885MEN1 2240/4885 |
| US-20040092537-A1 | Pyrrolo[2,3-d]pyrimidine and their use as purinergic receptor antagonists | CNR1, CNR2, CHRNA6 | NPC1 508/4885RAB9A 876/4885MEN1 4883/4885 |
| US-20080004295-A1 | NOVEL COMPOUNDS | SYK, BTK, LCK | NPC1 3702/4885RAB9A 3261/4885MEN1 4790/4885 |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | NPC1 4530/4885RAB9A 1164/4885MEN1 2835/4885 |
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | LRRK2, MAP3K20, MAP3K5 | NPC1 2422/4885RAB9A 917/4885MEN1 3663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.